Showing 38,901 - 38,920 results of 103,778 for search '(( e point decrease ) OR ( 5 ((step decrease) OR (((we decrease) OR (a decrease)))) ))', query time: 1.88s Refine Results
  1. 38901
  2. 38902
  3. 38903

    Combination treatment of berberine and solid lipid curcumin particles increased cell death and inhibited PI3K/Akt/mTOR pathway of human cultured glioblastoma cells more effectively... by Panchanan Maiti (1459852)

    Published 2019
    “…We found that co-treatment of SLCP and berberine produced more glioblastoma cell death, more DNA fragmentation, and significantly decreased ATP levels and reduced mitochondrial membrane potential than did single treatments in both glioblastoma cells lines. …”
  4. 38904
  5. 38905
  6. 38906
  7. 38907

    WTA stimulates in vitro T-cell activation by a MHC-II dependent mechanism. by Christopher Weidenmaier (240364)

    Published 2010
    “…An antibody to HLA-DR (5 µg/ml) inhibited T-cell proliferation induced by zwitterionic wt WTA (<i>p</i><0.0001) but not negatively charged <i>dltA</i> WTA. …”
  8. 38908
  9. 38909
  10. 38910
  11. 38911
  12. 38912

    Image_8_Distinct anti-NP, anti-RBD and anti-Spike antibody profiles discriminate death from survival in COVID-19.tif by Carolina do Prado Servian (17115112)

    Published 2023
    “…</p>Methods<p>We evaluated IgM, IgA, and IgG antibodies directed to the nucleocapsid (NP), IgA and IgG to the Spike protein and to the receptor-binding domain (RBD), and the presence of neutralizing antibodies (nAb), in a cohort of unvaccinated SARS-CoV-2 infected individuals, in the first 30 days of post-symptom onset (PSO) (T1).…”
  13. 38913

    Image_7_Distinct anti-NP, anti-RBD and anti-Spike antibody profiles discriminate death from survival in COVID-19.tif by Carolina do Prado Servian (17115112)

    Published 2023
    “…</p>Methods<p>We evaluated IgM, IgA, and IgG antibodies directed to the nucleocapsid (NP), IgA and IgG to the Spike protein and to the receptor-binding domain (RBD), and the presence of neutralizing antibodies (nAb), in a cohort of unvaccinated SARS-CoV-2 infected individuals, in the first 30 days of post-symptom onset (PSO) (T1).…”
  14. 38914

    Image_10_Distinct anti-NP, anti-RBD and anti-Spike antibody profiles discriminate death from survival in COVID-19.tif by Carolina do Prado Servian (17115112)

    Published 2023
    “…</p>Methods<p>We evaluated IgM, IgA, and IgG antibodies directed to the nucleocapsid (NP), IgA and IgG to the Spike protein and to the receptor-binding domain (RBD), and the presence of neutralizing antibodies (nAb), in a cohort of unvaccinated SARS-CoV-2 infected individuals, in the first 30 days of post-symptom onset (PSO) (T1).…”
  15. 38915

    Image_15_Distinct anti-NP, anti-RBD and anti-Spike antibody profiles discriminate death from survival in COVID-19.tif by Carolina do Prado Servian (17115112)

    Published 2023
    “…</p>Methods<p>We evaluated IgM, IgA, and IgG antibodies directed to the nucleocapsid (NP), IgA and IgG to the Spike protein and to the receptor-binding domain (RBD), and the presence of neutralizing antibodies (nAb), in a cohort of unvaccinated SARS-CoV-2 infected individuals, in the first 30 days of post-symptom onset (PSO) (T1).…”
  16. 38916

    Image_13_Distinct anti-NP, anti-RBD and anti-Spike antibody profiles discriminate death from survival in COVID-19.tif by Carolina do Prado Servian (17115112)

    Published 2023
    “…</p>Methods<p>We evaluated IgM, IgA, and IgG antibodies directed to the nucleocapsid (NP), IgA and IgG to the Spike protein and to the receptor-binding domain (RBD), and the presence of neutralizing antibodies (nAb), in a cohort of unvaccinated SARS-CoV-2 infected individuals, in the first 30 days of post-symptom onset (PSO) (T1).…”
  17. 38917

    Image_11_Distinct anti-NP, anti-RBD and anti-Spike antibody profiles discriminate death from survival in COVID-19.tif by Carolina do Prado Servian (17115112)

    Published 2023
    “…</p>Methods<p>We evaluated IgM, IgA, and IgG antibodies directed to the nucleocapsid (NP), IgA and IgG to the Spike protein and to the receptor-binding domain (RBD), and the presence of neutralizing antibodies (nAb), in a cohort of unvaccinated SARS-CoV-2 infected individuals, in the first 30 days of post-symptom onset (PSO) (T1).…”
  18. 38918

    Image_14_Distinct anti-NP, anti-RBD and anti-Spike antibody profiles discriminate death from survival in COVID-19.tif by Carolina do Prado Servian (17115112)

    Published 2023
    “…</p>Methods<p>We evaluated IgM, IgA, and IgG antibodies directed to the nucleocapsid (NP), IgA and IgG to the Spike protein and to the receptor-binding domain (RBD), and the presence of neutralizing antibodies (nAb), in a cohort of unvaccinated SARS-CoV-2 infected individuals, in the first 30 days of post-symptom onset (PSO) (T1).…”
  19. 38919

    Image_6_Distinct anti-NP, anti-RBD and anti-Spike antibody profiles discriminate death from survival in COVID-19.tif by Carolina do Prado Servian (17115112)

    Published 2023
    “…</p>Methods<p>We evaluated IgM, IgA, and IgG antibodies directed to the nucleocapsid (NP), IgA and IgG to the Spike protein and to the receptor-binding domain (RBD), and the presence of neutralizing antibodies (nAb), in a cohort of unvaccinated SARS-CoV-2 infected individuals, in the first 30 days of post-symptom onset (PSO) (T1).…”
  20. 38920

    Image_1_Distinct anti-NP, anti-RBD and anti-Spike antibody profiles discriminate death from survival in COVID-19.tif by Carolina do Prado Servian (17115112)

    Published 2023
    “…</p>Methods<p>We evaluated IgM, IgA, and IgG antibodies directed to the nucleocapsid (NP), IgA and IgG to the Spike protein and to the receptor-binding domain (RBD), and the presence of neutralizing antibodies (nAb), in a cohort of unvaccinated SARS-CoV-2 infected individuals, in the first 30 days of post-symptom onset (PSO) (T1).…”